Taner KAR, Yavuz ÇAKIR, Yıldıray YILDIRIM, ALİ AYATA

Results of dexamethasone implant in macular edema of variable etiologies

Maküla ödemi (MÖ) diabetik retinopati, retina ven kök ya da dal tıkanıklıkları, yaşa bağlı maküla dejenerasyonu ve üveit gibi hastalıklarda görme kaybının en önemli nedenidir. Çalışmamızda tek doz intravitreal deksametazon (İVD) implant enjeksiyonu sonrası en az 6 ay süre ile takip edilmiş retina ven kök veya dal tıkanıklığı, diabetik retinopati ve non enfektif posterior üveit'e bağlı MÖ tanısı alan 46 hastanın 50 gözüne ait bulgular retrospektif olarak değerlendirildi. Hastalar enjeksiyon öncesi ve enjeksiyondan sonra 7. gün, 1., 2., 3. ve 6. aylarda en iyi düzeltilmiş görme keskinliği (EDGK) ve santral maküla kalınlığı (SMK) açısından değerlendirildi. Tüm hastaların enjeksiyon öncesi ortalama EDGK ve SMK değerleri ile 7.gün 1., 2., 3. ve 6. aylardaki değerleri karşılaştırıldı ve sonuçlar istatiksel olarak anlamlı bulundu (p?0.05). Tüm hastalarda ve alt gruplarda maksimum EDGK artışı ve SMK azalması 2. ayda tespit edildi ve bu durum istatiksel olarak anlamlıydı (p

Farklı etyolojilere bağlı maküla ödeminde intravitreal deksametazon implantasyonu sonuçları

Macular edema is the most important cause of vision loss at the disease such as diabetic retinopathy, retinal vein root or branch occlusion, age related macular degeneration and uveitis. In our study, the findings from 50 eyes of 46 patients with the implementation of one dose intravitreal dexamethasone (IVD) diagnosed of retinal vein root or branch occlusion, diabetic retinopathy and macular edema related to non-enfective posterior uveitis, followed up at least 6 months after injection were evaluated retrospectively. Patients were evaluated of best corrected visual acuity (BCVA) and central macular thickness (CMT) before injection and 7th day, 1th, 2nd, 3th and 6th months after injection All patients mean CMT and BCVA outcomes were compared before injection with 7th day, 1th, 2nd, 3th and 6th months after injection and the results were statistically significant (p

PDF

___

1. Photocoagulation for diabetic macular edema. early treatment diabetic retinopathy study report number 1. early treatment diabetic retinopathy study research group. Arch Ophthalmol. 1985;103(12):1796-806.
2. Ayyıldız Ö, Durukan AH, Sobacı G, Erdurman FC, Hürmeriç V. Pediatrik üveitli olgularımızda klinik özellikler. Gülhane Med J. 2012;54(2):185-9.
3. Hansen LL, Wiek J, Wiederholt M. A randomised prospective study of treatment of non-ischemic central retinal vein occlusion by isovolaemic hemodilution. Br J Ophthalmol. 1989;73:895-9.
4. Kleinman ME, Baffi JZ, Ambati J. The multifactorial nature of retinal vascular disease. Ophthalmologica. 2010;224(1):16-24.
5. Wolfensberger TJ, Gregor ZJ. Macular edema – rationale for therapy. Dev Ophthalmol. 2010;47:49–58.
6. Photocoagulation for diabetic macular edema: Early Treatment diabetic retinopathy study report no. 4. the early treatment dia- betic retinopathy study research group. Int Ophthalmol Clin. 1987;27:265- 72.
7. Early photocoagulation for diabetic retinopa- thy. ETDRS report number 9. early treat- ment diabetic retinopathy study research group. Ophthalmology. 1991;98:766-85.
8. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol. 1984;98:271-282.
9. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthal Mology. 2010;117:1064-77.e1035.
10. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp D, Wolf-Schnurrbusch UE, Gekkieva M, Weichselberger A, Wolf S: Safety and effi- cacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399-405.
11. Ayyıldız O, Durukan AH, Ozgurtas T, Gunal A.A Comparison of Intravitreal Bevacizumab and Steroid Activity in an Experimental Uveitis Model. Curr Eye Res. 2015;40(12):1261-8.
12. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG: Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1102-12.e1101.
13. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F, Simader C, Burian G, Gerstner O, Weich- selberger A; RESTORE Study Group: The RE- STORE study: ranibizumab monotherapy or combined with laser versus laser monothera- py for diabetic macular edema. Ophthalmol Ogy. 2011;118:615-25.
14. Hardman JG, Limburd LE, Molinoff PB, Ruddon RW, Gilman AG, editors. Goodman and Gilman’s: The Pharmacological Basis of Therapeutics.9th ed. New York, NY, USA: McGraw-Hill; 1996
15. Kwak HW, D’Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol. 1992;110:259-66.
16. Maxwell DP Jr, Brent BD, Diamond JG, Wu L. Effect of intravitreal dexamethasone on ocular histopathology in a rabbit model of endophthalmitis. Ophthalmology. 1991;98:1370-5.
17. Ozurdex (dexamethasone intravitreal implant 0.7 mg). [Package insert].Irvine, CA, USA. Allergan, Inc; 2014.
18. Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52:80-6.
19. SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study report 6. Arch Ophthalmol. 2009;127:1115-28
20. Jabs DA1,Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN,Whitcup SM, Yocum D. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492-513.
21. Leopold IH. Nonsteroidal and steroidal anti-inflammatory agents. In: Sears ML, Tarkkanen A, eds. Surgical Pharmacology of the Eye. New York: Raven Press. 1985:83-133.
22. Myung JS, Aaker GD, Kiss S Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant. Clin Ophthalmol. 2010;4:1423-6
23. Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, Welty D. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52(1):80-6.
24. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125(3):309-17.
25. Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904-14.
26. Zucchiatti , Lattanzio R, Querques G, Querques L, Del Turco C, Cascavilla ML, Bandello F. Intravitreal dexamethasone implant in patients with persistent diabetic macular edema. Ophthalmologica. 2012;228(2):117-22.
27. Dutra Medeiros M, Postorino M, Navarro R, Garcia-Arumí J, Mateo C, Corcóstegui B. Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica. 2014;231(3):141-6.
28. Gado AS, Macky TA. Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion-related macular oedema: a prospective randomized comparison. Clin Experiment Ophthalmol. 2014;42(7):650-5.
29. Pichi F, Specchia C, Vitale L, Lembo A, Morara M, Veronese C, Ciardella AP, Nucci P. Combination therapy with dexamethasone intravitreal implant and macular grid laser in patients with branch retinal vein occlusion. Am J Ophthalmol. 2014;157(3):607-15.
30. Haller J, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY,Whitcup SM; OZURDEX GENEVA Study Group. Randomized, shamcontrolled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134-46.
31. Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li XY, Cui H, Whitcup SM; Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Ach Ophthalmol. 2011;129(5):545- 53.
32. Armaly ME. Statistical attributes of the steroid hypertensive response in the clinically normal eye, I: the demonstration of three levels of response. Invest Ophthalmol. 1965;4:187-97.
33. Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol. 1965;4:198-205.